Published in J Control Release on April 18, 2005
Paclitaxel distribution in poly(ethylene glycol)/poly(lactide-co-glycolic acid) blends and its release visualized by coherent anti-Stokes Raman scattering microscopy. J Control Release (2007) 0.89
Docetaxel-loaded pluronic p123 polymeric micelles: in vitro and in vivo evaluation. Int J Mol Sci (2011) 0.80
Improved Treatment of Pancreatic Cancer With Drug Delivery Nanoparticles Loaded With a Novel AKT/PDK1 Inhibitor. Pancreas (2016) 0.77
PLA micro- and nano-particles. Adv Drug Deliv Rev (2016) 0.75
Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 2.77
Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials (2005) 1.55
Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials (2007) 1.49
Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials (2012) 1.39
Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials (2006) 1.32
Folate-decorated poly(lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials (2007) 1.29
Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel. Biomaterials (2003) 1.27
Formulation of Docetaxel by folic acid-conjugated d-α-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy. Biomaterials (2011) 1.25
The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials (2006) 1.21
PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and drug loading ratio. Pharm Res (2003) 1.20
Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res (2013) 1.20
Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials (2009) 1.18
Targeted delivery of paclitaxel using folate-decorated poly(lactide)-vitamin E TPGS nanoparticles. Biomaterials (2008) 1.14
Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials (2013) 1.12
Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev (2012) 1.11
Paclitaxel drug delivery systems. Expert Opin Drug Deliv (2013) 1.09
Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials (2010) 1.08
Targeting and imaging cancer cells by folate-decorated, quantum dots (QDs)- loaded nanoparticles of biodegradable polymers. Biomaterials (2008) 1.07
In vitro investigation on poly(lactide)-Tween 80 copolymer nanoparticles fabricated by dialysis method for chemotherapy. Biomacromolecules (2006) 1.04
In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials (2005) 1.02
Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel. J Biomed Mater Res A (2006) 1.01
Theranostic liposomes of TPGS coating for targeted co-delivery of docetaxel and quantum dots. Biomaterials (2012) 1.01
Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. J Control Release (2013) 1.00
Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials (2008) 1.00
In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res (2008) 1.00
Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials (2012) 0.96
Superparamagnetic iron oxide--loaded poly(lactic acid)-D-alpha-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent. Biomaterials (2010) 0.94
Vitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm (2011) 0.93
Effects of lipid chain unsaturation and headgroup type on molecular interactions between paclitaxel and phospholipid within model biomembrane. J Colloid Interface Sci (2005) 0.93
Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials (2007) 0.93
Self-assembled nanoparticles of poly(lactide)--Vitamin E TPGS copolymers for oral chemotherapy. Int J Pharm (2006) 0.92
Effects of lipid chain length on molecular interactions between paclitaxel and phospholipid within model biomembranes. J Colloid Interface Sci (2004) 0.91
Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol succinate and folic acid as a prodrug for targeted chemotherapy. J Biomed Mater Res A (2010) 0.91
Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine (Lond) (2010) 0.91
Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm (2010) 0.90
Enhanced oral bioavailability of paclitaxel formulated in vitamin E-TPGS emulsified nanoparticles of biodegradable polymers: in vitro and in vivo studies. J Pharm Sci (2010) 0.90
A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials (2010) 0.90
Multimodal tumor imaging by iron oxides and quantum dots formulated in poly (lactic acid)-D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoparticles. Biomaterials (2011) 0.89
Effects of material hydrophobicity on physical properties of polymeric microspheres formed by double emulsion process. J Control Release (2002) 0.89
Poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy. Int J Pharm (2007) 0.89
In vitro and in vivo evaluation of methoxy polyethylene glycol-polylactide (MPEG-PLA) nanoparticles for small-molecule drug chemotherapy. Biomaterials (2007) 0.88
Multifunctional silica nanoparticles for targeted delivery of hydrophobic imaging and therapeutic agents. Int J Pharm (2011) 0.88
Vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicine. Nanomedicine (Lond) (2012) 0.87
Vitamin E (D-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succinate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRI. Biomaterials (2011) 0.87
Folic acid-functionalized two-photon absorbing nanoparticles for targeted MCF-7 cancer cell imaging. Chem Commun (Camb) (2011) 0.86
Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int J Pharm (2010) 0.86
Pharmaceutical stability aspects of nanomedicines. Nanomedicine (Lond) (2009) 0.85
Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles. Biomaterials (2013) 0.83
d-alpha-Tocopheryl polyethylene glycol 1000 succinate (TPGS) modified poly(l-lactide) (PLLA) films for localized delivery of paclitaxel. Int J Pharm (2007) 0.83
Formulation, characterization, and in vitro evaluation of quantum dots loaded in poly(lactide)-vitamin E TPGS nanoparticles for cellular and molecular imaging. Biotechnol Bioeng (2008) 0.82
Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier. Nanomedicine (Lond) (2011) 0.82
Block copolymer micelles for nanomedicine. Nanomedicine (Lond) (2012) 0.82
Effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within the lipid monolayer at the air-water interface. J Colloid Interface Sci (2006) 0.82
Polyethylenimine coating to produce serum-resistant baculoviral vectors for in vivo gene delivery. Biomaterials (2009) 0.82
Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. Biomaterials (2013) 0.81
Theranostic liposomes for cancer diagnosis and treatment: current development and pre-clinical success. Expert Opin Drug Deliv (2012) 0.81
Nanomedicine: enhancement of chemotherapeutical efficacy of docetaxel by using a biodegradable nanoparticle formulation. Curr Pharm Des (2010) 0.80
Nanomedicine for multimodality treatment of cancer. Nanomedicine (Lond) (2012) 0.80
Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond) (2010) 0.80
siRNA-based nanomedicine. Nanomedicine (Lond) (2013) 0.80
Herceptin functionalized polyhedral oligomeric silsesquioxane - conjugated oligomers - silica/iron oxide nanoparticles for tumor cell sorting and detection. Biomaterials (2011) 0.80
Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine (Lond) (2009) 0.79
Prodrug micelle-based nanomedicine for cancer treatment. Nanomedicine (Lond) (2013) 0.79
Autophagy inhibition strategy for advanced nanomedicine. Nanomedicine (Lond) (2014) 0.79
Nanoimmunotherapy: application of nanotechnology for sustained and targeted delivery of antigens to dendritic cells. Nanomedicine (Lond) (2012) 0.79
Trastuzumab-conjugated vitamin E TPGS liposomes for sustained and targeted delivery of docetaxel. Expert Opin Drug Deliv (2013) 0.79
Facile synthesis of water-stable magnetite nanoparticles for clinical MRI and magnetic hyperthermia applications. Nanomedicine (Lond) (2010) 0.79
Vitamin E TPGS prodrug micelles for hydrophilic drug delivery with neuroprotective effects. Int J Pharm (2012) 0.79
Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials (2011) 0.79
Nanotheranostics: advanced nanomedicine for the integration of diagnosis and therapy. Nanomedicine (Lond) (2014) 0.79
Nanomedicine against multidrug resistance in cancer treatment. Nanomedicine (Lond) (2012) 0.78
Nanomedicine for oral chemotherapy. Nanomedicine (Lond) (2011) 0.78
Nanopharmacology of liposomes developed for cancer therapy. Nanomedicine (Lond) (2010) 0.78
Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. Nanomedicine (Lond) (2014) 0.78
Conjugated polymer loaded nanospheres with surface functionalization for simultaneous discrimination of different live cancer cells under single wavelength excitation. Anal Chem (2011) 0.78
Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine (Lond) (2012) 0.78
Nanothermotherapy by high performance magnetic nanoparticles. Nanomedicine (Lond) (2010) 0.78
Copolymer technology for advanced nanomedicine. Nanomedicine (Lond) (2011) 0.77
Polymeric nanoparticulates for cancer immunotherapy. Nanomedicine (Lond) (2013) 0.77
CD20 Antibody-Conjugated Immunoliposomes for Targeted Chemotherapy of Melanoma Cancer Initiating Cells. J Biomed Nanotechnol (2015) 0.77
Nanohydrogels as a prospective member of the nanomedicine family. Nanomedicine (Lond) (2013) 0.77
Star-shaped block polymers as a molecular biomaterial for nanomedicine development. Nanomedicine (Lond) (2014) 0.77
Nanomedicine for diabetes treatment. Nanomedicine (Lond) (2011) 0.76
Targeted nanomedicine for detection and treatment of circulating tumor cells. Nanomedicine (Lond) (2011) 0.76
Nanomedicine for the treatment of triple-negative breast cancer. Nanomedicine (Lond) (2014) 0.76
DSC and EPR investigations on effects of cholesterol component on molecular interactions between paclitaxel and phospholipid within lipid bilayer membrane. Int J Pharm (2007) 0.76
Herceptin®-conjugated nanocarriers for targeted imaging and treatment of HER2-positive cancer. Nanomedicine (Lond) (2011) 0.75
Multimodal imaging for cancer detection. Nanomedicine (Lond) (2010) 0.75
The synergistic effect of herceptin and docetaxel in polylactide-D-α-tocopheryl polyethylene glycol succinate (PLA-TPGS) nanoparticles. J Control Release (2011) 0.75
Investigation of molecular interactions between paclitaxel and DPPC by Langmuir film balance and differential scanning calorimetry. J Pharm Sci (2004) 0.75
Synthesis of hydrophilic superparamagnetic magnetite nanoparticles via thermal decomposition of Fe(acac), in 80 vol% TREG + 20 vol% TREM. J Nanosci Nanotechnol (2011) 0.75
Nanotechnology for multimodal imaging. Nanomedicine (Lond) (2011) 0.75
Nanomedicine for treatment of cancer stem cells. Nanomedicine (Lond) (2014) 0.75
Thermochemotherapy mediated by novel solar-planet structured magnetic nanocomposites for glioma treatment. J Nanosci Nanotechnol (2012) 0.75